Home
About Us
Our Vision & Mission
Who We Are
Our History
Message from CMD-Desk
Our Leadership
People and Values
Our Values
Testimonials
Our Major Accreditations
Meet Our Team
Our Partners
Our Business
Ethical Business
Generic Healthcare Business
Export Business
Research & Development
Products
Ethical
Allopathic Medicine
General Health
Gynaecology
Pediatric
Ayurvedic Medicine
Generic Healthcare
Capacities
Quality
Manufacturing
Global Business Unit
Samba Unit
Research & Development
Investor Relations
Disclosure under Regulation 46
Details of Business
MOA
Brief Profile of Directors
Composition of BOD
Composition of Committees
Corporate Goverance
Notice of Board Meetings
Financial Results (Quarterly)
Credit Rating
Audited Financial Results of Subsidiaries
Annual Returns
Notice of AGM/EGM
Notices
Annual Reports
Voting Results
Transcript
Business Responsiblity Reports
Shareholders Information
Shareholder Services
Unclamied Dividend
Details of Transfer under SEBI Circular
Amalgamation
Preferential Issue
Corporate Announcements
Integrated Corporate Goverance
Shareholding Pattern
Other Announcements
Publications
Regulation 30
Related Party Transactions
Regulation 47
Responsibility
Sustainability
CSR
EHS
Opportunities
Join Us
Careers
Contact Us
Location
SCO 850, Shivalik Enclave, Sector 13, NAC Manimajra, Chandigarh - 160101
Phone
0172-5061850
Email
support@indswiftlabs.com
Home
Disclaimer
Call us:
0172-5061850
Email us:
support@indswiftlabs.com
Regd. Office:
SCO 850, Shivalik Enclave, Sector 13, NAC Manimajra, Chandigarh - 160101
Home
About Us
Our Vision & Mission
Who We Are
Our History
Message from CMD-Desk
Our Leadership
People and Values
Our Values
Testimonials
Our Major Accreditations
Meet Our Team
Our Partners
Our Business
Ethical Business
Generic Healthcare Business
Export Business
Research & Development
Products
Ethical
Allopathic Medicine
General Health
Gynaecology
Pediatric
Ayurvedic Medicine
Generic Healthcare
Capacities
Quality
Manufacturing
Global Business Unit
Samba Unit
Research & Development
Investor Relations
Disclosure under Regulation 46
Details of Business
MOA
Brief Profile of Directors
Composition of BOD
Composition of Committees
Corporate Goverance
Notice of Board Meetings
Financial Results (Quarterly)
Credit Rating
Audited Financial Results of Subsidiaries
Annual Returns
Notice of AGM/EGM
Notices
Annual Reports
Voting Results
Transcript
Business Responsiblity Reports
Shareholders Information
Shareholder Services
Unclamied Dividend
Details of Transfer under SEBI Circular
Amalgamation
Preferential Issue
Corporate Announcements
Integrated Corporate Goverance
Shareholding Pattern
Other Announcements
Publications
Regulation 30
Related Party Transactions
Regulation 47
Responsibility
Sustainability
CSR
EHS
Opportunities
Join Us
Careers
Contact Us
Home
About Us
Our Vision & Mission
Who We Are
Our History
Message from CMD-Desk
Our Leadership
People and Values
Our Values
Testimonials
Our Major Accreditations
Meet Our Team
Our Partners
Our Business
Ethical Business
Generic Healthcare Business
Export Business
Research & Development
Products
Ethical
Allopathic Medicine
General Health
Gynaecology
Pediatric
Ayurvedic Medicine
Generic Healthcare
Capacities
Quality
Manufacturing
Global Business Unit
Samba Unit
Research & Development
Investor Relations
Disclosure under Regulation 46
Details of Business
MOA
Brief Profile of Directors
Composition of BOD
Composition of Committees
Corporate Goverance
Notice of Board Meetings
Financial Results (Quarterly)
Credit Rating
Audited Financial Results of Subsidiaries
Annual Returns
Notice of AGM/EGM
Notices
Annual Reports
Voting Results
Transcript
Business Responsiblity Reports
Shareholders Information
Shareholder Services
Unclamied Dividend
Details of Transfer under SEBI Circular
Amalgamation
Preferential Issue
Corporate Announcements
Integrated Corporate Goverance
Shareholding Pattern
Other Announcements
Publications
Regulation 30
Related Party Transactions
Regulation 47
Responsibility
Sustainability
CSR
EHS
Opportunities
Join Us
Careers
Contact Us
Preferential Issue
Home
Investor Relations
Preferential Issue
Monitoring Agency Report for Quarter ended 31.12.2025 —
[Download 718Kb]
Monitoring Agency Report Quarter ended 30.09.2025 —
[Download 650Kb]
Intimation for Conversion of Security 01.08.2025 —
[Download 622Kb]
Intimation for Conversion of Security 22.07.2025 —
[Download 584Mb]
Monitoring Agency Report Quarter Ended 30.06.2025 —
[Download 1.99Mb]
Intimation for Conversion of Security 02.07.2025 —
[Download 738Kb]
Intimation under Reg 29(1) 04.07.2025 —
[Download 745Kb]
Monitoring Agency Report for the quarter ended 31.03.2025 —
[Download 622Kb]
Allotment Resolution —
[Download 522Kb]
Monitoring Agency Report – December 2024 —
[Download 598Kb]
Corrigendum to the Notice of EGM dated 28.06.2024 —
[Download 1.02Mb]
Notice calling EGM for considering Preferential Issue —
[Download 891Kb]
Summary VR to determine the Floor price as per SEBI ICDR Regulations —
[Download 1.28Mb]
Pricing Certificate —
[Download 4.78Mb]
Outcome of BM dated 27.06.2024 —
[Download 3.58Mb]
Outcome of Preferential issue Committee dated 28.06.2024 —
[Download 1.88Mb]
PCS Certificate —
[Download 810Kb]
Monitoring Agency Report —
[Download 573Kb]
